Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of Physical Injury for Dispatched Citizen Responders to Out-of-Hospital Cardiac Arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Time Trends in Simple Congenital Heart Disease Over 39 Years: A Danish Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Intensive Lifestyle Intervention Increases Plasma Midregional Proatrial Natriuretic Peptide Concentrations in Overweight Children

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Age At Menopause: A Female Risk Factor of Stroke?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Zhe Kang Law
  • Michael Desborough
  • Ian Roberts
  • Rustam Al-Shahi Salman
  • Timothy J England
  • David J Werring
  • Thompson Robinson
  • Kailash Krishnan
  • Robert Dineen
  • Ann Charlotte Laska
  • Nils Peters
  • Juan Jose Egea-Guerrero
  • Michal Karlinski
  • Hanne Christensen
  • Christine Roffe
  • Daniel Bereczki
  • Serefnur Ozturk
  • Jegan Thanabalan
  • Rónán Collins
  • Maia Beridze
  • Philip M Bath
  • Nikola Sprigg
Vis graf over relationer

Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain. Methods and Results This is an exploratory analysis of the TICH-2 (Tranexamic Acid in Intracerebral Hemorrhage-2) double-blind, randomized, placebo-controlled trial, which studied the efficacy of tranexamic acid in patients with spontaneous ICH within 8 hours of onset. Multivariable logistic regression and ordinal regression were performed to explore the relationship between pre-ICH antiplatelet therapy, and 24-hour hematoma expansion and day 90 modified Rankin Scale score, as well as the effect of tranexamic acid. Of 2325 patients, 611 (26.3%) had pre-ICH antiplatelet therapy. They were older (mean age, 75.7 versus 66.5 years), more likely to have ischemic heart disease (25.4% versus 2.7%), ischemic stroke (36.2% versus 6.3%), intraventricular hemorrhage (40.2% versus 27.5%), and larger baseline hematoma volume (mean, 28.1 versus 22.6 mL) than the no-antiplatelet group. Pre-ICH antiplatelet therapy was associated with a significantly increased risk of hematoma expansion (adjusted odds ratio [OR], 1.28; 95% CI, 1.01-1.63), a shift toward unfavorable outcome in modified Rankin Scale (adjusted common OR, 1.58; 95% CI, 1.32-1.91) and a higher risk of death at day 90 (adjusted OR, 1.63; 95% CI, 1.25-2.11). Tranexamic acid reduced the risk of hematoma expansion in the overall patients with ICH (adjusted OR, 0.76; 95% CI, 0.62-0.93) and antiplatelet subgroup (adjusted OR, 0.61; 95% CI, 0.41-0.91) with no significant interaction between pre-ICH antiplatelet therapy and tranexamic acid (P interaction=0.248). Conclusions Antiplatelet therapy is independently associated with hematoma expansion and unfavorable functional outcome. Tranexamic acid reduced hematoma expansion regardless of prior antiplatelet therapy use. Registration URL: https://www.isrctn.com; Unique identifier: ISRCTN93732214.

OriginalsprogEngelsk
Artikelnummere019130
TidsskriftJournal of the American Heart Association
Vol/bind10
Udgave nummer5
Sider (fra-til)1-12
Antal sider12
ISSN2047-9980
DOI
StatusUdgivet - feb. 2021

ID: 66519825